Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway
Drug Design, Development and Therapy · 2026
DOI: 10.2147/dddt.s556850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Zuoxi Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Ji…. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Cholagogues and Choleretics, Colorectal Neoplasms, Colon. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Ursodeoxycholic acid (UDCA) demonstrates potential therapeutic effects against colorectal cancer (CRC) due to its anti-inflammatory and immunomodulatory properties; however, its precise molecular mechanisms remain incompletely understood.
Methods
This study employed an integrative approach combining network pharmacology, molecular docking, and in vivo validation in an AOM/DSS-induced mouse model to investigate the specific molecular targets of UDCA and its associated effects on the gut microenvironment.
Results
UDCA significantly alleviated colitis-associated tumorigenesis and reduced tumor burden, which was associated with the inhibition of the PI3K/Akt/mTOR signaling pathway. Molecular docking and experimental verification identified EGFR as a key upstream target directly engaged by UDCA to suppress this oncogenic axis. Furthermore, UDCA treatment improved the tumor microenvironment, characterized by suppressed pro-inflammatory cytokines, regulated metabolic gene expression (including CYP19A1 and HMGCR), and a shift toward gut microbiota homeostasis through the enrichment of beneficial taxa and short-chain fatty acids.
Conclusion
These findings suggest that UDCA exerts its anti-tumor effects primarily through direct inhibition of the EGFR-mediated PI3K/Akt/mTOR pathway, accompanied by partial restoration of the intestinal immune-metabolic microenvironment. This study provides new mechanistic insights supporting the therapeutic application of UDCA in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, People's Republic of China.
- Jiangxi Trauma Clinical Medical Research Center, Department of Emergency Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Zitieren
APA
Huang, Z., Hong, H., Yang, H., & He, C. (2026). Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s556850
Vancouver
Huang Z, Hong H, Yang H, He C. Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s556850
BibTeX
@article{Huang2026,
author = {Huang, Zuoxi and Hong, Huazhang and Yang, Hongbao and He, Chong},
title = {Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway},
journal = {Drug Design, Development and Therapy},
year = {2026},
doi = {10.2147/dddt.s556850}
}
EUVIMED